Free Trial

CytoDyn (OTCMKTS:CYDY) Trading 2.1% Higher - Here's Why

CytoDyn logo with Medical background

CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) was up 2.1% during mid-day trading on Friday . The company traded as high as $0.12 and last traded at $0.12. Approximately 1,859,693 shares changed hands during mid-day trading, a decline of 12% from the average daily volume of 2,111,096 shares. The stock had previously closed at $0.12.

CytoDyn Stock Performance

The stock has a 50 day moving average of $0.12 and a two-hundred day moving average of $0.14. The stock has a market cap of $145.98 million, a PE ratio of -5.95 and a beta of 0.14.

CytoDyn (OTCMKTS:CYDY - Get Free Report) last released its quarterly earnings results on Tuesday, October 15th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter.

CytoDyn Company Profile

(Get Free Report)

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CytoDyn Right Now?

Before you consider CytoDyn, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytoDyn wasn't on the list.

While CytoDyn currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

7 Large-Cap Stocks Headed for Strong, Steady Gains in 2025

7 Large-Cap Stocks Headed for Strong, Steady Gains in 2025

While 2025 may not deliver massive returns, so MarketBeat analyst Chris Markoch shares his list of seven stocks primed for consistent performance.

Related Videos

The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Small Caps, Financials & Bitcoin Lead the Rising Bull Market: Chris Rowe’s Top Picks
Massive Market Moves Following Trump Win: Tesla, JP Morgan, & Bitcoin Soar

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines